FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.
How this was made

The 30-second read
Why it matters
Traders should treat this as a first-in-class FDA approval catalyst for Regeneron, with immediate focus on commercialization readiness (access program, provider administration), safety monitoring (boxed meningococcal warning), and patient eligibility (AChR-positive only).
Market read
FDA approval plus Phase 3 efficacy metrics are likely to drive near-term sentiment for Regeneron, while boxed-warning logistics and missing launch/pricing details add uncertainty to the magnitude/timing of revenue impact.
What to watch
Approval covers only AChR-positive patients, and the combination arm showed no numerical advantage over cemdisiran alone, which may narrow perceived differentiation versus existing C5-pathway approaches.
Background
Cemdisiran (Livsayis) is a subcutaneous siRNA dosed every 3 months that targets C5 by degrading its mRNA, aiming to reduce complement activation driving AChR-positive gMG.
Ticker impact
Regeneron’s cemdisiran (Livsayis) received FDA approval for AChR-positive generalized myasthenia gravis, with Phase 3 NIMBLE efficacy and boxed safety warning details.
Likely positive repricing as investors add a new, differentiated neurology revenue stream, partially offset by safety and launch/pricing uncertainty.
The article is a primary regulatory approval event for Regeneron’s product, includes efficacy outcomes (MG-ADL, QMG) and explicit boxed-warning/availability constraints, which are the key drivers for trader reassessment.
Market effects
Strengthens the neurology and complement-targeting siRNA narrative, potentially increasing investor attention to C5/complement and RNAi platforms in autoimmune neuromuscular disease.
EU regulatory submission is pending with a decision expected in 2H 2027, which can shape longer-dated sentiment for European biotech/neurology peers.
First-in-class FDA approval may influence global payer and guideline discussions for gMG, affecting competitive positioning for other gMG therapies.
Counterpoint
The article provides no US launch date or pricing, and the boxed meningococcal risk plus prophylaxis/vaccination logistics could slow uptake versus investors’ initial enthusiasm.
Key entities
- drugCemdisiran (Livsayis)
Subcutaneous siRNA therapy targeting C5, dosed every 3 months, approved for adults with AChR-positive generalized myasthenia gravis.
- companyRegeneron Pharmaceuticals
Sponsor of cemdisiran and the company announcing FDA approval and NIMBLE trial results.
- clinical_trialNIMBLE trial
Phase 3 randomized, double-blind, placebo-controlled study supporting approval; primary endpoint MG-ADL at week 24.




